Radioactive drug RYZ401 targets Hard-to-Treat tumors in first human trial
NCT ID NCT07165132
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 104 adults with advanced or inoperable tumors will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Facility
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Facility
RECRUITINGLexington, Kentucky, 40536, United States
-
Research Facility
RECRUITINGSt Louis, Missouri, 63104, United States
-
Research Facility
RECRUITINGSalt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.